AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Patient-Reported Outcomes and Quality of Life
Panel highlights FACT-P and functional wellbeing showing minimal overall QoL detriment with capivasertib addition.
Play episode from 01:03:35
Transcript
